Mabpharm Ltd
02181
Company Profile
Business description
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
Contact
Lujia Road East, Koutai Road West
Block G79, China Medical City
Taizhou225300
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
383
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,133.30 | 31.50 | -0.34% |
| CAC 40 | 8,167.73 | 63.89 | 0.79% |
| DAX 40 | 24,205.36 | 414.71 | 1.74% |
| Dow JONES (US) | 48,739.41 | 238.14 | 0.49% |
| FTSE 100 | 10,567.65 | 83.52 | 0.80% |
| HKSE | 25,677.40 | 427.92 | 1.69% |
| NASDAQ | 22,807.48 | 290.79 | 1.29% |
| Nikkei 225 | 55,713.27 | 1,467.73 | 2.71% |
| NZX 50 Index | 13,603.47 | 72.35 | 0.53% |
| S&P 500 | 6,869.50 | 52.87 | 0.78% |
| S&P/ASX 200 | 8,910.10 | 33.30 | -0.37% |
| SSE Composite Index | 4,114.17 | 31.70 | 0.78% |